The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1270
September 24, 2007
View Complete Issue         Table of Contents 2019 
Fentanyl Buccal Tablet (Fentora) for Breakthrough Pain
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Fentanyl Buccal Tablet (Fentora) for Breakthrough Pain
September 24, 2007 (Issue: 1270)
The FDA has approved a transmucosal tablet formulation of fentanyl citrate (Fentora - Cephalon) for management of breakthrough pain in opioid-tolerant patients with cancer. An oral transmucosal fentanyl lozenge on a stick (Actiq, and others) is also...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Fentanyl Buccal Tablet (Fentora) for Breakthrough Pain
Article code: 1270b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.